Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion submitted an Investigational New Drug (IND) application to South Korea’s Ministry of Food and Drug Safety (MFDS) for a global Phase 3 clinical trial of CT-P44, a Darzalex biosimilar candidate, targeting patients with refractory or relapsed multiple myeloma.
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: Application for Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar) in South Korea
- Regulatory Body: Ministry of Food and Drug Safety (MFDS), South Korea
- Application & Confirmation Date: 2025-03-20
- Clinical Trial Details
- Study Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group Phase 3 Trial to Compare the Efficacy and Safety of Subcutaneous CT-P44 versus Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma
- Phase: Global Phase 3
- Target Indication: Refractory or Relapsed Multiple Myeloma
- Registration Number: EU CT number 2024-518588-36-00
- Patient Count: 486 subjects
- Duration: 2 years
- Purpose: To demonstrate biosimilarity between CT-P44 and the reference drug Darzalex in terms of efficacy and safety
- Regulatory Process & Investment Risks
- Statistically, the probability of a clinical-stage drug candidate receiving final pharmaceutical authorization is approximately 10%.
- Commercialization plans may be modified or abandoned based on trial outcomes during clinical testing or licensing processes.
- The company aims to demonstrate biosimilarity through this Phase 3 trial.
- Content of this disclosure will be utilized in upcoming press releases and IR materials.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of MFDS Approval for the Phase 3 Clinical Trial Plan
This disclosure serves as official notification regarding the submission of the global Phase 3 IND application for CT-P44 to South Korea’s MFDS. Tracking whether the regulatory authority grants final approval for the submitted trial plan is important for determining whether the pipeline can officially proceed with clinical trial execution and patient dosing in South Korea. Relevant updates can be confirmed through subsequent major management disclosures, periodic reports, or official company IR materials.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
